DNX-2401IMO, this particular adenovirus (DNX-2401) clinical trial in Glioblastoma was certainly one of the more interesting and promising during the past few years.
As you can see, the results are somewhat inconclusive and merely suggest rationale for further small scale studies prior to moving to a large P2.
I do hope ONCY delivers something more substantive on Thursday. Else we're in for a few more years of seeing the SP hover along a horizontal path.
Best of luck this week. Maybe a pop up 20% on Monday morining?
https://ascopost.com/news/may-2023/combined-delivery-of-dnx-2401-plus-pembrolizumab-may-be-safe-and-effective-in-patients-with-recurrent-glioblastoma/